Skip to main content

Table 3 Relationship between biomarkers variations between Day 0 and Day 3–4 and the outcome

From: Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients

  Survivors Non-survivors p-value for univariate comparison Adjusted***
HR [95% CI]
p-value
Lymphocyte ratio* 16.4 [− 4.5, 53.3] − 23.6 [− 54.5, 20.6] 0.02 0.9 [0.8–1.0] 0.05
Delta Lymphocyte** − 160.0 [− 395.0, 65.0] 0 [− 40.0, 460.0] 0.01 1.2 [1.1–1.4] 0.01
CRP ratio − 45.7 [− 62.6, 14.9] 13.9 [− 20.3, 32.1] 0.04 1.0 [0.9–1.1] 0.44
Delta CRP 39.5 [− 12.0, 114.6] − 34.0 [− 68.7, 65.7] 0.05 0.6 [0.4–0.9] 0.01
Fibrinogen ratio − 0.02 [− 0.88, 0.29] 0.16 [− 0.01, 0.35] 0.155 1.41 [0.77–2.57] 0,25
Delta Fibrinogen − 0.11 [− 1.18, 0.54] 0.36 [− 0.03, 1.00] 0.05 1.40 [0.96–2.05] 0.08
IL-6 ratio − 14.5 [− 29.3, 0.4] − 6.6 [− 21.0, 0.2] 0.55 1.2 [0.8–1.6] 0.37
Delta IL-6 − 0.7 [− 1.6, 0] − 0.4 [− 1.0, 0] 0.66 0.9 [0.5–1.8] 0.83
  1. Results are given as Median [IQR] and Hazard Ratio (HR) [95%CI], *Ratio: percentage of change from Day 0 value; ** delta between Day0 and Day 3–4 values; ***Adjusted on SOFA at ICU admission and time from symptom onset to first dosage